This site is intended only for healthcare professionals resident in Egypt
Eliquis® 5 mg BID is the recommended dose for stroke prevention in NVAF1
Dose reduction for special population1
The recommended dose of Eliquis® is 2.5 mg taken orally BID in patients with NVAF and at least two of the following characteristics:1
ASA: acetyl salicylic acid; BID: twice daily; INR: International Normalized Ratio; NOAC: nonvitamin K antagonist oral anticoagulant; NVAF: nonvalvular atrial fibrillation; VKA: vitamin K antagonist.
References: 1. Eliquis 2.5 mg/ 5 mg Egyptian Drug Authority approved leaflet 17/08/2022. Revision Date: February 2022. 2. Granger CB, Alexander JH, McMurray JJ, et al.Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981-992. 3. Steffel J, Verhamme P, Potpara TS, et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J.2018;39(16):1330-1393.
Adverse events should be reported. Adverse events can be reported to [email protected]
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
The product information provided in this site is intended only for Healthcare Professionals of Egypt. The products discussed herein may have different product labeling in different countries.
Copyright © 2023 Pfizer biopharmaceutical LLC. All rights reserved.
These pages are not intended for patients or members of the general public. This portal contains healthcare promotional content.
If you select ‘No’, you will be redirected to Pfizer.com, the global Pfizer website.
I confirm that I am a healthcare professional resident in Egypt.